Lipophile-conjugated sulfated oligosaccharides as novel microbicides against HIV-1

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 286-295

  Said, Joanna ^a   Trybala, Edward ^a   Andersson, Elin ^a   Johnstone, Ken ^b   Liu, Ligong ^b   Wimmer, Norbert ^b   Ferro, Vito ^b   Bergström, Tomas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Progen Pharmaceuticals Limited   (Australia)

Author keywords

HIV 1; HSV 2; Microbicides; Virucidal activity

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHOLESTANOL; MUPARFOSTAT; PI 88; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS PARTICLE;

ANIMALS; ANTI-INFECTIVE AGENTS; CELLS, CULTURED; CHOLESTANOL; EPITHELIAL CELLS; HERPESVIRUS 2, HUMAN; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OLIGOSACCHARIDES; SULFATES;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952671609     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.03.011     Document Type: Article

References (54)

1. Anderson R.A., Feathergill K.A., Diao X.H., Cooper M.D., Kirkpatrick R., Herold B.C., Doncel G.F., Chany C.J., Waller D.P., Rencher W.F., Zaneveld L.J. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J. Androl. 2002, 23:426-438.
2. Baba M., Nakajima M., Schols D., Pauwels R., Balzarini J., De Clercq E. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res. 1988, 9:335-343.
3. Balmer D.H., Gikundi E., Kanyotu M., Waithaka R. The negotiating strategies determining coitus in stable heterosexual relationships. Health Transit. Rev. 1995, 5:85-95.
4. Borggren M., Repits J., Kuylenstierna C., Sterjovski J., Churchill M.J., Purcell D.F., Karlsson A., Albert J., Gorry P.R., Jansson M. Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology 2008, 5:28.
5. Cohen J. AIDS Research. Microbicide fails to protect against HIV. Science 2008, 319:1026-1027.
6. Crublet E., Andrieu J.P., Vives R.R., Lortat-Jacob H. The HIV-1 envelope glycoprotein GP120 features four heparan sulfate binding domains, including the coreceptor binding site. J. Biol. Chem. 2008, 283:15193-15200.
7. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
8. Demaria S., Bushkin Y. Soluble CD4 induces the binding of human immunodeficiency virus type 1 to cells via the V3 loop of glycoprotein 120 and specific sites in glycoprotein 41. AIDS Res. Hum. Retroviruses 1996, 12:281-290.
9. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
10. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Collman R.G., Doms R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
11. Duff R., Rapp F. Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nat. New Biol. 1971, 233:48-50.
12. Ekblad M., Adamiak B., Bergstrom T., Johnstone K.D., Karoli T., Liu L., Ferro V., Trybala E. A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus. Antiviral Res. 2010, 10.1016/j.antiviral.2010.02.318.
13. El-Sadr W.M., Mayer K.H., Maslankowski L., Hoesley C., Justman J., Gai F., Mauck C., Absalon J., Morrow K., Mâsse B., Soto-Torres L., Kwiecien A. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 2006, 20:1109-1116.
14. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
15. Ferro V., Fewings K., Palermo M.C., Li C. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88. Carbohydr. Res. 2001, 332:183-189.
16. Fletcher P.S., Shattock R.J. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr. Opin. Investig. Drugs 2008, 9:189-200.
17. Gunalp A. Growth and cytopathic effect of rubella virus in a line of Green monkey kidney cells. Proc. Soc. Exp. Biol. Med. 1965, 118:185-190.
18. Holmberg S.D., Stewart J.A., Gerber A.R., Byers R.H., Lee F.K., O'Malley P.M., Nahmias A.J. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988, 259:1048-1050.
19. Holmes K.K., Levine R., Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull. World Health Organ. 2004, 82:454-461.
20. Horal P., Hall W.W., Svennerholm B., Lycke J., Jeansson S., Rymo L., Kaplan M.H., Vahlne A. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:5754-5758.
21. Javan C.M., Gooderham N.J., Edwards R.J., Davies D.S., Shaunak S. Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res. Hum. Retroviruses 1997, 13:875-880.
22. Johnstone K.D., Karoli T., Liu L., Dredge K., Copeman E., Li C.P., Davis K., Hammond E., Bytheway I., Kostewicz E., Chiu F.C., Shackleford D.M., Charman S.A., Charman W.N., Harenberg J., Gonda T.J., Ferro V. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J. Med. Chem. 2010, 53:1686-1699.
23. Kapiga S.H., Sam N.E., Bang H., Ni Q., Ao T.T., Kiwelu I., Chiduo S., Ndibe U., Seage G., Coplan P., Shao J., Rosenberg Z.F., Essex M. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J. Infect. Dis. 2007, 195:1260-1269.
24. Karoli T., Liu L., Fairweather J.K., Hammond E., Li C.P., Cochran S., Bergefall K., Trybala E., Addison R.S., Ferro V. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J. Med. Chem. 2005, 48:8229-8236.
25. Keet I.P., Lee F.K., van Griensven G.J., Lange J.M., Nahmias A., Coutinho R.A. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin. Med. 1990, 66:330-333.
26. Keller M.J., Zerhouni-Layachi B., Cheshenko N., John M., Hogarty K., Kasowitz A., Goldberg C.L., Wallenstein S., Profy A.T., Klotman M.E., Herold B.C. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J. Infect. Dis. 2006, 193:27-35.
27. Kilmarx P.H., van de Wijgert J.H., Chaikummao S., Jones H.E., Limpakarnjanarat K., Friedland B.A., Karon J.M., Manopaiboon C., Srivirojana N., Yanpaisarn S., Supawitkul S., Young N.L., Mock P.A., Blanchard K., Mastro T.D. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a Phase II Clinical Trial. J. Acquir. Immune Defic. Syndr. 2006, 43:327-334.
28. Malonza I.M., Mirembe F., Nakabiito C., Odusoga L.O., Osinupebi O.A., Hazari K., Chitlange S., Ali M.M., Callahan M., Van Damme L. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005, 19:2157-2163.
29. Microbicides Development Program, 2009. HIV " prevention" gel PRO 2000 proven ineffective, http://www.mdp.mrc.ac.uk/downloads/MDP%2520Microbicides%2520release%2520111209%2520%2520Embargoed%2520until%2520141209.pdf.
30. Mondor I., Ugolini S., Sattentau Q.J. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 1998, 72:3623-3634.
31. Moulard M., Lortat-Jacob H., Mondor I., Roca G., Wyatt R., Sodroski J., Zhao L., Olson W., Kwong P.D., Sattentau Q.J. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 2000, 74:1948-1960.
32. Neurath A.R., Strick N., Li Y.Y. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect. Dis. 2002, 2:27.
33. Nyberg K., Ekblad M., Bergström T., Freeman C., Parish C.R., Ferro V., Trybala E. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antiviral Res. 2004, 63:15-24.
34. Pearce-Pratt R., Phillips D.M. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 1996, 54:173-182.
35. Piret J., Lamontagne J., Bestman-Smith J., Roy S., Gourde P., Désormeaux A., Omar R.F., Juhász J., Bergeron M.G. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J. Clin. Microbiol. 2000, 38:110-119.
36. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 2001, 276:13433-13441.
37. Quinn T.C. AIDS in Africa: evidence for heterosexual transmission of the human immunodeficiency virus. N. Y. State J. Med. 1987, 87:286-289.
38. Repits J., Oberg M., Esbjörnsson J., Medstrand P., Karlsson A., Albert J., Fenyö E.M., Jansson M. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 2005, 86:2859-2869.
39. Repits J., Sterjovski J., Badia-Martinez D., Mild M., Gray L., Churchill M.J., Purcell D.F., Karlsson A., Albert J., Fenyö E.M., Achour A., Gorry P.R., Jansson M. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 2008, 379:125-134.
40. Roderiquez G., Oravecz T., Yanagishita M., Bou-Habib D.C., Mostowski H., Norcross M.A. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 1995, 69:2233-2239.
41. Rusconi S., Moonis M., Merrill D.P., Pallai P.V., Neidhardt E.A., Singh S.K., Willis K.J., Osburne M.S., Profy A.T., Jenson J.C., Hirsch M.S. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 1996, 40:234-236.
42. Schaeffer D.J., Krylov V.S. Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol. Environ. Saf. 2000, 45:208-227.
43. Stamm W.E., Handsfield H.H., Rompalo A.M., Ashley R.L., Roberts P.L., Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988, 260:1429-1433.
44. Tao J., Hu Q., Yang J., Li R., Li X., Lu C., Chen C., Wang L., Shattock R., Ben K. In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res. 2007, 75:227-233.
45. Tao W., Richards C., Hamer D. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses 2008, 24:925-929.
46. Trifonova R.T., Doncel G.F., Fichorova R.N. Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob. Agents Chemother. 2009, 53:1490-1500.
47. Ulin P.R. African women and AIDS: negotiating behavioral change. Soc. Sci. Med. 1992, 34:63-73.
48. UNAIDS, 2009. AIDS Epidemic Update December 2009, http://www.unaids.org/.
49. Varga C.A. Sexual decision-making and negotiation in the midst of AIDS: youth in KwaZulu-Natal, South Africa. Health Trans. Rev. 1997, 7(Suppl. 3):45-67.
50. Witvrouw M., De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen. Pharmacol. 1997, 29:497-511.
51. Vivès R.R., Imberty A., Sattentau Q.J., Lortat-Jacob H. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J. Biol. Chem. 2005, 280:21353-21357.
52. Vzorov A.N., Bozja J., Dixon D.W., Marzilli L.G., Compans R.W. Parameters of inhibition of HIV-1 infection by small anionic microbicides. Antiviral Res. 2007, 73:60-68.
53. Yu G., Gunay N.S., Linhardt R.J., Toida T., Fareed J., Hoppensteadt D.A., Shadid H., Ferro V., Li C., Fewings K., Palermo M.C., Podger D. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur. J. Med. Chem. 2002, 37:783-791.
54. Zhang Y.J., Hatziioannou T., Zang T., Braaten D., Luban J., Goff S.P., Bieniasz P.D. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J. Virol. 2002, 76:6332-6343.